Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Alimemazine→

Alimemazine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
84-96-8
Molecular formula
C18H22N2S
Molecular weight
298.4 g/mol
Drug class
First-generation phenothiazine antihistaminesedative and antipruritic agent
Mechanism of action
Antagonises peripheral and central histamine H1 receptors. Additional anticholinergic, antidopaminergic and sedative effects may contribute to its clinical actions; receptor selectivity varies by dose.
Indications / reported uses
  • Symptomatic treatment of allergic disorders including pruritus and urticaria in product-authorised settings
  • Short-term symptomatic treatment of severe pruritus and selected sleep-related or premedication uses only where covered by the specific formulation and national product information

Sources: UK product information — Alimemazine (trimeprazine) · NLM MeSH — Alimemazine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Alimemazine Environmental Risk Assessment (ERA) (the Alimemazine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.